The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, ...

Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast ...

Roche claimed the results make its drug giredestrant the first of its kind, a so-called oral SERD, to show a benefit in the ...

Roche (OTCQX:RHHBY) unit Genentech announced on Tuesday that giredestrant, a selective estrogen receptor degrader (SERD), ...

Roche has reported another phase 3 win for its oral selective estrogen receptor degrader (SERD). Success at a planned interim ...

Olema Pharmaceuticals (OLMA) surges after Roche's breast cancer data, but caution is urged as key clinical results are ...

Roche announced positive phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endocrine treatment for people with oestrogen receptor ...

The company said the drug helped women with a form of early breast cancer live longer without the disease progressing, ...

Roche's giredestrant has experienced a notable turnaround after initial challenges in phase 2 trials. The company previously reported a phase 3 win for the drug in September, which was further ...

Shares in Swiss healthcare company Roche surged to an eight-month high on Tuesday after results from a clinical trial of its ...

As Roche works to switch certain patients with breast cancer over to a fixed-dose combination of two medicines, its ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.